QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients 期刊论文 ANNALS OF SURGICAL ONCOLOGY, 2018, 卷号: 25, 期号: 8 作者:  Cui, ChuanLiang;  Lian, Bin;  Zhou, Li;  Song, Xin;  Zhang, XiaoShi 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04 Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients 期刊论文 ANNALS OF SURGICAL ONCOLOGY, 2018, 卷号: 25, 期号: 8 作者:  Cui, ChuanLiang;  Lian, Bin;  Zhou, Li;  Song, Xin;  Zhang, XiaoShi 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study 期刊论文 European Journal of Cancer, 2018, 卷号: Vol.100, 页码: 1-7 作者:  Xinan Sheng;  Dengfeng Cao;  Jianlin Yuan;  Fangjian Zhou;  Qiang Wei 收藏  |  浏览/下载：5/0  |  提交时间：2019/02/25 Cisplatin  Gemcitabine  Metastatic collecting duct carcinoma  Progression-free survival  Sorafenib   A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2016, 卷号: 34, 期号: 15 作者:  Chi, Zhihong;  Si, Lu;  Sheng, Xinan;  Cul, Chuanliang;  Tang, Bixia 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/04 A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma 会议论文 作者:  Sheng, Xi Nan;  Si, Lu;  Chi, Zhihong;  Cui, Chuanliang;  Li, Si Ming 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/04 A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE II STUDY TO COMPARE BEVACIZUMAB PLUS SORAFENIB VERSUS SORAFENIB FOR THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT02330783) 会议论文 作者:  Guo, Jun 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/19 A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783) 会议论文 作者:  Guo, Jun;  Sheng, Xi Nan;  Chi, Zhihong;  Cui, Chuanliang;  Si, Lu 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/19